Morning Brief — Friday, August 21, 2026

Market Overview

Bitcoin breaking above $77,000 is the dominant theme this morning, pulling every crypto-linked equity sharply higher and lifting broader risk sentiment after Thursday’s equity sell-off. Deere’s strong Q3 beat and raised guidance is providing a constructive read on industrials, while Moderna’s 177%+ weekly surge on cancer vaccine data is keeping healthcare in focus. Rising bond yields and Trump’s geopolitical threats remain headwinds, but futures are recovering — Friday’s tape is shaping up as a battle between crypto momentum and rate anxiety.

Claude’s Call

UP — Bitcoin’s breakout above the 2026 ceiling is a genuine sentiment catalyst that pulls institutional risk appetite forward into the weekend, and with DE’s solid earnings confirming the industrial cycle isn’t broken, the path of least resistance is a modest Friday recovery bounce off Thursday’s lows — though rising yields cap the upside, so don’t expect fireworks beyond +0.5% on the S&P 500.

Top Movers

MRNA (+8.23%) — $144.29 → $174.38 (+20.9% upside to 20d high / prior resistance) Thesis: This is a real catalyst — Moderna and Merck published Phase 3 data showing their personalized mRNA melanoma vaccine meaningfully reduces recurrence risk, and the read-through to MRNA’s broader oncology pipeline is legitimate. The stock has gone from $45 to $144 in weeks, but it’s sitting right at the 23.6% Fibonacci retracement ($143.93) from the 6-month swing — which is now acting as support, not resistance. The question isn’t whether the catalyst is real; it’s whether you’re chasing. Healthcare is genuinely breaking out as a sector, and this is the poster child. But a 127% weekly gain means the easy money is behind you. Levels: Exit at $174 (20d high / 6mo high resistance). Support at $125 (38.2% fib retracement) — a break below $143 would be an early warning sign.

DE (+6.94%) — $620.94 → $674.71 (+8.7% upside) Thesis: This is a clean fundamental beat — revenue +4.9% YoY to $12.61B, EPS $5.10 vs. consensus, 14.4% operating margin, and a raised full-year guide. Management is signaling a potential bottom in the ag equipment cycle while construction remains strong, and the technology adoption story (precision agriculture, autonomy) is intact. Technically, DE bounced off its 50-day SMA ($604) with conviction and is now reclaiming the $616 fib support level. This is a buy-the-dip that already worked — the question is whether there’s follow-through to $674 (fib ext 1.272). Levels: Exit at $674.71 (1.272 fib extension). Support at $604 (50d SMA) — a logical stop zone if the move reverses.

COIN (+5.34%) — $181.55 → $199.12 (+9.7% upside) Thesis: Bitcoin breaking $77K is the cleanest catalyst here — Coinbase is the purest regulated exchange play on BTC momentum, and Trump’s push for the CLARITY Act is adding genuine regulatory tailwind that could be structural, not just a headline pop. COIN is sitting right at its 20-day high ($182.82) and has cleared its 50d SMA ($158) convincingly. Trump crypto regulatory headlines historically have a 48-hour half-life, but if BTC holds above $75K into the weekend, COIN has room to run toward the 23.6% fib resistance at $199. Levels: Exit at $199.12 (23.6% fib). Support at $170.82 (61.8% fib retracement) — strong floor if crypto sentiment sours.

FIGR (+7.48%) — $38.76 → $48.28 (+24.6% upside) Thesis: Figure Technology just posted a stellar Q2 — CLM volume surged 132% to $4.3B, Figure Connect hit 65% of mix, and three analyst upgrades followed. The deliberately shrinking take rate (because the capital-light marketplace is scaling) is the key insight: analysts who understand the business model flip are more constructive than those who see margin compression. RSI at 24.39 is deeply oversold despite today’s 7% gain — this has been beaten down and is now bouncing with real fundamental support. The 50d SMA is at $29.99; current price is $38.76, meaning the technical rebuild is underway but not overextended. Levels: Exit at $48.28 (1.272 fib extension). Support at $36.26 (38.2% fib retracement).

AUPH (+6.80%) — $17.27 → $19.89 (+15.2% upside) Thesis: Aurinnia just locked in a Teva patent settlement that delays generic LUPKYNIS competition until December 2036 — that’s 10 years of protected exclusivity. Q2 EPS beat by 47%. The stock still looks cheap on valuation despite a 74% 3-year run, and the IP moat just got meaningfully wider. Technically, AUPH is hitting its 20-day high ($17.27) with room to the fib extension at $19.89. This isn’t a momentum chase — it’s a valuation re-rating story with a clear new catalyst. Levels: Exit at $19.89 (1.272 fib extension). Support at $16.84 (38.2% fib) — stop below $16.29 (50% fib).

HMY (+6.63%) — $23.48 → $26.10 (+11.1% upside) Thesis: Gold miners are ripping and HMY is at a 6-month high. RSI at 77.8 is overbought, so be eyes-open, but the gold macro is genuinely supportive — State Street sees $5,000 gold by early 2027, and HMY has operating leverage to the gold price that makes it a high-beta play on the commodity. This isn’t a stock-specific catalyst; it’s sector rotation into hard assets as yields rise and geopolitical risk stays elevated. The 50d SMA ($16.77) is far below current price — the trend is strong, but overbought technicals warrant a tight stop. Levels: Exit at $26.10 (1.272 fib extension). Support at $20.89 (23.6% fib retracement) — wide stop, small position sizing recommended given RSI.

NTES (+6.92%) — $128.10 → $141.16 (+10.2% upside) Thesis: NetEase reported Q2 gaming revenue +10% YoY, gross margins improved to 76.1%, and AI tools are expanding margins further. At $128, NTES is sitting right on the 23.6% fib support ($128.16) after a pullback — clean entry point. The stock is cited as 23% undervalued on fundamental analysis. China tech has its own risks (regulatory, geopolitical), but gaming fundamentals here are solid and the margin story is compelling. Levels: Exit at $141.16 (1.272 fib extension). Support at $124.43 (38.2% fib) / $126.84 (50d SMA).

Headlines to Watch

Bitcoin Breaks $77K, Trump Pushes CLARITY Act — Regulatory clarity for crypto would be a structural re-rating event for COIN, MSTR, and CRCL; if the bill moves forward, this isn’t just a Trump pump — it’s a fundamentals shift worth watching closely.
Moderna/Merck Melanoma Vaccine Phase 3 Success — The mRNA oncology platform is now validated beyond COVID; this is the catalyst MRNA has needed for two years and has read-through implications for the entire biotech sector.
Deere Raises FY2026 Guidance, 14.4% Operating Margin — A potential ag cycle bottom signal — watch CNH Industrial (CNH) and AGCO for sympathy moves, and note that construction equipment strength is a GDP-positive signal.
Alibaba -4.77%: AI Spending Surges 75%, Profit Misses — The “invest now, profit later” trade is causing indigestion at BABA; this is a warning shot for all hyperscalers burning cash on AI capex — the market is starting to demand returns.
Walmart Rare Miss, -0.36% — WMT missing is unusual and worth monitoring as a consumer health indicator; if the strongest retailer in America is seeing softness, discretionary names are vulnerable.
$207 Billion Left Banking System in One Month — Quiet but potentially significant liquidity signal; could mean rotation into crypto/equities or early stress in financial plumbing — worth monitoring credit spreads.
Fabrinet Beat but Shares Fall 7% AH, Dragging Peers — AI networking hardware demand is strong but guidance may have disappointed; watch Marvell (MRVL) and Amphenol (APH) for read-through to the AI capex cycle.

Claude’s Top Picks

DE (+6.94% today, +1.4% week) — $620.94 → $674.71 (+8.7% upside) Valuation: No comps data available, but at ~17x forward earnings for an industrial with a beaten-down ag cycle turning, DE looks reasonably valued versus peers like CAT and CNH. Upside: Clean earnings beat, raised guidance, and a 50d SMA bounce with ag cycle bottom narrative — institutional buyers have a clear thesis to add exposure here. Risk: Tariff escalation (Trump “economic warfare” threats) could hit farm equipment demand rapidly if trade tensions with key agricultural markets flare.

AUPH (+6.80% today, +13.77% week) — $17.27 → $19.89 (+15.2% upside) Valuation: Described as “still cheap” after a 74% 3-year run with a meaningful IP moat just extended — a rare combination of momentum and value in biotech. Upside: A decade of generic-free runway for LUPKYNIS combined with a 47% EPS beat is an unusually clean setup — the IP settlement is a quantifiable, durable catalyst. Risk: LUPKYNIS is a single-product story; any adverse safety data or formulary coverage loss would disproportionately impact the stock given concentration risk.

FIGR (+7.48% today, +23.32% week) — $38.76 → $48.28 (+24.6% upside) Valuation: No comps available, but three analyst upgrades post-earnings suggest the street sees valuation support — fintech peers with 132% volume growth don’t typically trade at distressed multiples. Upside: The capital-light marketplace model scaling to 65% of mix is a business model transformation that the market is only beginning to price in, and the RSI at 24.39 (deeply oversold) suggests this was over-punished before today’s bounce. Risk: Take rate compression is the bear case — if the marketplace model grows but economics erode faster than volume scales, the unit economics story breaks down.

COIN (+5.34% today, +22.28% week) — $181.55 → $199.12 (+9.7% upside) Valuation: COIN typically trades at a premium to crypto fundamentals given exchange business quality — currently near 20d highs but not overextended versus its 6-month range. Upside: Bitcoin above $77K is the fuel, and the CLARITY Act regulatory tailwind is a genuine structural catalyst that could compress the regulatory risk premium that has weighed on COIN’s multiple for years. Risk: Trump regulatory headlines are historically high-volatility/low-follow-through — if the CLARITY Act stalls in Congress again (it has before), this 22% weekly run unwinds fast.

NTES (+6.92% today, +2.38% week) — $128.10 → $141.16 (+10.2% upside) Valuation: Cited at 23% undervalued post-earnings with 76.1% gross margins — for a gaming company with 10% revenue growth and AI-driven margin expansion, this looks genuinely cheap versus global gaming peers. Upside: The combination of new title launches, global expansion, and AI tooling driving margin improvement is a multi-quarter thesis — Q2 beat was the first confirmation. Risk: China regulatory risk is always the wildcard for NTES — any new gaming restrictions from Beijing would override the fundamental story immediately, and geopolitical tensions remain elevated.

Avoid

MRNA — After a 177%+ weekly surge, MRNA is sitting exactly at the 23.6% fib retracement and has already run from $45 to $144; the cancer vaccine catalyst is real but the risk/reward is asymmetric against you at these levels — any disappointing follow-up data or profit-taking wave will be violent.

HMY (+6.63%) — RSI at 77.8 is a screaming overbought signal, the stock is at its 6-month high with no obvious near-term technical target that isn’t already priced in, and the catalyst (gold price momentum) is entirely macro-driven with no company-specific edge — sector sympathy plays at RSI extremes are the classic retail trap.

MSTR (+6.22%) — Trading well below all key Fibonacci retracement levels (current $119 vs. 61.8% fib at $125.72, 50% at $139), meaning Bitcoin would need to sustain a massive further rally just to recover to mid-range levels; the 6-month high was $195 and you’re buying a leveraged BTC proxy at a 40% discount to highs after a 28% weekly run — the leverage cuts both ways and the RSI at 12.65 tells you this has been a broken trade until very recently.

WSB Sentiment Check

MRNA — WSB says: BEARISH (30% bullish) Claude says: AGREE — WSB is unusually right here; after a 127% weekly run the crowd buying momentum is walking into a confirmed overbought setup, and with only 30% bulls on WSB (typically a contrarian buy signal), even the degens are nervous — that’s telling.

RDDT — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — RDDT is sitting 15% below its 6-month high at $152.53, technically below the 61.8% fib support at $152.95 (barely), and below its 50d SMA at $172.99 — the chart is not constructive; WSB bulls are talking their book on the stock they literally live on, and that’s the definition of biased sentiment.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — At $979 with a 50d SMA at $964 providing near-term support and memory cycle recovery underway, the bull case has legs, but the stock is off 19% from its $1,213 6-month high and hasn’t reclaimed key fib levels — the mixed sentiment is appropriate; this is a “show me” setup heading into earnings, not a conviction buy.

WMT — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Walmart just posted a rare miss and the stock is sitting at its 6-month low of $103.52 — the 80% bullish WSB read looks like bottom-fishing at an inflection point that hasn’t confirmed yet; wait for the stock to reclaim $113 (50d SMA) before declaring the dip buyable.

SNDK — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — SNDK is trading at $1,585, below its 50d SMA at $1,654 and well off the $2,335 6-month high; the mixed sentiment is honest, but at 32% below highs with memory capex tailwinds, there’s a bottoming case — just not a high-conviction one given the lack of volume confirmation (vol_vs_avg: 0.07).

Earnings Scorecard

BABA — REPORTED | Stock: -4.77% | Reaction: Sell-the-rip justified AI spending up 75% crushed near-term profit, and the market correctly punished the “invest now, profit never” fear — at $4.41 EPS with a -4.77% reaction, the market is telling you the AI capex story needs to show returns before BABA gets credit; analyst target at $190 suggests the dip is overdone long-term, but near-term sentiment is broken.

ROST — REPORTED | Stock: +3.76% | Reaction: Underreaction — still a buy Ross beat and raised full-year guidance while consumers are under pressure — that’s a quality signal. Headlines note shares were set to open +8% but closed only +3.76%, meaning the intraday buyers gave back gains; the gap between analyst target ($257.50) and current price implies further upside, and off-price retail outperforming in a stressed consumer environment is a durable thesis.

KLAR — REPORTED | Stock: +2.5% | Reaction: Reaction misleading — structural concerns remain Klarna cut its 2026 outlook, announced leadership changes, and JPMorgan downgraded — a +2.5% reaction after a headline -20.9% crash suggests a relief bounce from oversold levels, not a fundamental repair; avoid chasing this one, the analyst target at $21.27 is well above current price but the guide cut is a credibility issue.

BIDU — REPORTED | Stock: +2.14% | Reaction: Modest bounce from deeply oversold — cautious Baidu’s -14.2% pre-reaction and then +2.14% bounce smells like dead-cat territory; the “weak Q2 earnings and faster AI-first shift” narrative is not resolved by a 2% bounce, and the analyst target at $151.30 requires a significant re-rating that needs fundamental confirmation first.

TGT — REPORTED | Stock: +2.03% | Reaction: Fairly valued reaction Target’s $9.59 EPS and modest positive reaction suggests no major surprise either way — in a tough consumer environment, “didn’t get worse” is passing the bar; analyst target at $160.32 suggests moderate upside but this isn’t a name to get excited about near-term.

WMT — REPORTED | Stock: -0.36% | Reaction: Market under-reacted — more downside risk A rare miss from Walmart — the most defensive consumer name in the index — is being treated as a non-event, but it shouldn’t be; the consumer is showing cracks even at the value end, and with WMT at its 6-month low and the 50d SMA at $113.59 far above, the -0.36% reaction understates the signal. Wait for a confirmed base before buying.

DE — REPORTED | Stock: +6.94% | Reaction: Justified — this is a legitimate buy 9% EPS beat, raised guidance, 14.4% operating margin, and a potential ag cycle bottom — DE’s +6.94% is exactly what a clean industrial beat deserves. Not overdone; the 50d SMA bounce makes this technically clean too.

FN (Fabrinet) — REPORTED | Stock: -0.31% | Reaction: Market close reaction understates after-hours reality Fabrinet beat but dropped 7% after hours, dragging peers — the flat close masks a post-earnings selloff that will likely weigh on the open today. When a beat causes a 7% AH drop, the guidance or mix was the miss; tread carefully in AI optical networking names today.

LOW — REPORTED | Stock: -0.18% | Reaction: Fairly priced — housing still soft Lowe’s in-line print and cautious outlook in a soft housing market is exactly what the flat reaction implies; the 9% undervaluation note is interesting but requires a housing recovery catalyst that isn’t here yet.

HD — REPORTED | Stock: -0.02% | Reaction: Market correctly shrugged — nothing new Home Depot at -0.02% on a $14.28 EPS print says the market saw exactly what it expected — no thesis change, no action needed.

All levels referenced are from provided Fibonacci retracement/extension data and SMAs. This brief is for informational purposes and does not constitute investment advice.